Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

Also called NCT03205150

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 107 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03205150
  • EudraCT 2017-002046-71
Other papers using this trial's data
  • Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study Nature medicine, 2022-07 DOI, PubMed 35725922, PMC10061496 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, Israel, Netherlands, Russia, Taiwan, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03205150. Randomized; triple masking; primary purpose treatment. Start 2017-10-04 (actual); primary completion 2019-11-11 (actual). Results posted on 2021-01-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
Condition
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Intervention (Drug)
LIK066
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03205150
Content hash
051e437499057d1e9278ab2c5c1863e4e649cd0393011373b997133c2be5a936